Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P40337: Variant p.Leu158Pro

von Hippel-Lindau disease tumor suppressor
Gene: VHL
Feedback?
Variant information Variant position: help 158 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 158 (L158P, p.Leu158Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In VHLD; type I-II; abolishes release from chaperonin complex and the interaction with Elongin BC complex. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 158 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 213 The length of the canonical sequence.
Location on the sequence: help PSLNVDGQPIFANITLPVYT L KERCLQVVRSLVKPENYRRL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         P--------SLNVDGQPIFAN---ITLPVYTLKERCL-QVVRSLVK--PENYRR-----L

                              P--------SLNVDGQPIFAN---ITLPVYTLKERCL-QVV

Mouse                         P--------SLNVDGQPIFAN---ITLPVYTLKERCL-QVV

Rat                           P--------SLNVDGQPIFAN---ITLPVYTLKERCL-QVV

Caenorhabditis elegans        P--------EPAPRMNLIVRNHCVITMKVQSLRE----IAG

Drosophila                    PIRVRVPKSQQSPDQLVDVRSEVLIHFPMRSLRENCLWLVA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 213 von Hippel-Lindau disease tumor suppressor
Region 157 – 166 Interaction with Elongin BC complex
Helix 158 – 169



Literature citations
Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.
Feldman D.E.; Thulasiraman V.; Ferreyra R.G.; Frydman J.;
Mol. Cell 4:1051-1061(1999)
Cited for: INTERACTION WITH CHAPERONES; VARIANT VHLD PRO-158; Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.
Zbar B.; Kishida T.; Chen F.; Schmidt L.; Maher E.R.; Richards F.M.; Crossey P.A.; Webster A.R.; Affara N.A.; Ferguson-Smith M.A.; Brauch H.; Glavac D.; Neumann H.P.H.; Tisherman S.; Mulvihill J.J.; Gross D.J.; Shuin T.; Whaley J.; Seizinger B.; Kley N.; Olschwang S.; Boisson C.; Richard S.; Lips C.H.M.; Linehan W.M.; Lerman M.I.;
Hum. Mutat. 8:348-357(1996)
Cited for: VARIANTS VHLD LEU-65; TRP-65; GLY-74; PHE-76 DEL; ILE-76; HIS-78; SER-78; THR-78; ARG-80; ASN-80; ILE-80; SER-81; ALA-86; LEU-86; ARG-88; SER-88; PRO-89; ARG-101; ARG-111; ASN-111; CYS-114; TYR-115; CYS-117; PRO-118; GLY-121; LEU-130; PRO-158; VAL-158; PRO-161; ARG-162; PHE-162; TYR-162; TRP-162; ARG-164; GLN-167; TRP-167; GLY-170; PRO-178; VAL-180; ARG-184; PRO-184; LYS-186; GLN-188 AND TRP-200; Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S.; Richard S.; Boisson C.; Giraud S.; Laurent-Puig P.; Resche F.; Thomas G.;
Hum. Mutat. 12:424-430(1998)
Cited for: VARIANTS VHLD LYS-52; LEU-65; LYS-70; ASN-80; ARG-80; SER-86; SER-88; LEU-91; ALA-104; PRO-105; GLN-115; CYS-117; PRO-118; LEU-130; LYS-131; SER-136; ASP-156; CYS-156; ILE-157; PRO-158; GLN-161; TRP-162; PHE-166; GLN-167; TRP-167; GLY-170; PRO-188 AND TRP-200;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.